Dengue: development of preventive vaccines A systematic review
DOI:
https://doi.org/10.56294/piii2024342Keywords:
Dengue, Serotypes, Vaccination, PreventionAbstract
Introduction: Dengue is a viral disease transmitted by a vector, which has 4 different serotypes. This infection by any viral strain can be asymptomatic or cause variable and unique clinical manifestations ranging from a mild febrile syndrome to severe dengue. Because there is no treatment that acts effectively and the vector control measures are not as successful as expected to prevent or impede the proliferation of the virus, the formulation of a vaccine becomes an effective measure to stop the development of the disease.
Material and methods: The present systematic review has used search engines such as Pubmed and Google academic to search for articles of the clinical and randomized trial type, finding articles regarding dengue and vaccination. Results: (A total of 15 RCTs have been used for a fundamentalistic analysis of the predefined variables to understand dengue and vaccination.). Conclusion: Dengue is the most widespread disease transmitted by mosquito bites in the world. This high prevalence shows the importance of vaccines in controlling the disease. Furthermore, it is worth highlighting the attention necessary for a diagnostic test due to crossimmunization. Thus we conclude that the greater the knowledge about the vaccines made and those that are in the development phase, taking into consideration a good diagnosis is of utmost importance for the control of the disease and its consequences
References
1. Echegaray F, Laing P, Hernandez S, Marquez S, Harris A, Laing I, et al. Adapting Rapid Diagnostic Tests to Detect Historical Dengue Virus Infections. Front Immunol. 23 de julio de 2021;12:703887.
2. Pintado Silva J, Fernandez-Sesma A. Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art. J Gen Virol [Internet]. 1 de marzo de 2023 [citado 19 de diciembre de 2023];104(3). Disponible en: https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.001831
3. Wang WH, Urbina AN, Lin CY, Yang ZS, Assavalapsakul W, Thitithanyanont A, et al. Targets and strategies for vaccine development against dengue viruses. Biomed Pharmacother. diciembre de 2021;144:112304.
4. Wilder-Smith A. Dengue vaccine development: status and future. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. enero de 2020;63(1):40-4.
5. Halstead SB. Is Dengue Vaccine Protection Possible? Clin Infect Dis. 7 de enero de 2022;74(1):156-60.
6. Thisyakorn U, Tantawichien T. Dengue vaccine: a key for prevention. Expert Rev Vaccines. 2 de junio de 2020;19(6):499-506.
7. Wellekens K, Betrains A, De Munter P, Peetermans W. Dengue: current state one year before WHO 2010–2020 goals. Acta Clin Belg. 4 de marzo de 2022;77(2):436-44.
8. Rabaa MA, Girerd-Chambaz Y, Duong Thi Hue K, Vu Tuan T, Wills B, Bonaparte M, et al. Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy. eLife. 5 de septiembre de 2017;6:e24196.
9. Harapan H, Fajar JK, Sasmono RT, Kuch U. Dengue vaccine acceptance and willingness to pay. Hum Vaccines Immunother. 3 de abril de 2017;13(4):786-90.
10. Torres-Flores JM, Reyes-Sandoval A, Salazar MI. Dengue Vaccines: An Update. BioDrugs. mayo de 2022;36(3):325-36.
11. Halstead SB. Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. Am J Trop Med Hyg. 5 de octubre de 2016;95(4):741-5.
12. Patel SS, Rauscher M, Kudela M, Pang H. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. Clin Infect Dis. 8 de febrero de 2023;76(3):e1350-9.
13. Henein S, Adams C, Bonaparte M, Moser JM, Munteanu A, Baric R, et al. Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection. J Clin Invest. 1 de julio de 2021;131(13):e147066.
14. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 24 de septiembre de 2015;373(13):1195-206.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Kariny Pereira Mendonça, Gerardo Laube (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
